Potent LNA oligonucleotides for the inhibition of HIF-1A expression
View Patent ↗The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-( T x )G x G x c s a s a s g s c s a s t s c s c s T x G x T-3′ and 5′-( G x )T x T x a s c s t s g s c s c s t s t s c s T x T x A -3′, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/LNA nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The LNA oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (HIF-1a), e.g. in the treatment of cancer diseases, inhibiting angiogenesis, inducing apoptosis, preventing cellular proliferation, or treating an angiogenic disease, e.g. diabetic retinopathy, macular degeneration (ARMD), psoriasis, rheumatoid arthritis and other inflammatory diseases.
1. An LNA oligonucleotide consisting of the sequence:
(SEQ ID NO. 1)
5′-T s G s G s c s a s a s g s c s a s t s c s c s T s G s T s a-3′
wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, lower case letters designate a 2-deoxynucleotide, and subscript “s” designates a phosphorothioate link between neighbouring nucleotides/LNA nucleotide analogues.
2. A pharmaceutical composition comprising an LNA oligonucleotide consisting of the sequence:
(SEQ ID NO. 1)
5′-T s G s G s c s a s a s g s c s a s t s c s c s T s G s T s a-3′
wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, lower case letters designate a 2-deoxynucleotide, and subscript “s” designates a phosphorothioate link between neighboring nucleotides/LNA nucleotide analogues, and a pharmaceutically acceptable diluent, carrier or adjuvant.
3. The pharmaceutical composition according to claim 2 , which comprises an aqueous carrier and has a pH in the range of 4.0-8.5 and an ionic strength of 20-2000 mM.
4. The pharmaceutical composition according to claim 2 , which is adapted for intraocular administration.
5. The pharmaceutical composition according to claim 2 further comprising at least one chemotherapeutic agent.
6. A kit comprising
(a) a first component containing an LNA oligonucleotide consisting of the sequence:
(SEQ ID NO. 1)
5′-T s G s G s c s a s a s g s c s a s t s c s c s T s G s T s a-3′
wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, lower case letters designate a 2-deoxynucleotide, and subscript “s” designates a phosphorothioate link between neighboring nucleotides/LNA nucleotide analogues in solid form, and
(b) a second component containing saline or a buffer solution adapted for reconstitution of said LNA oligonucleotides.
7. The pharmaceutical composition according to claim 5 , wherein the at least one chemotherapeutic agent is a taxane.
8. The pharmaceutical composition according to claim 7 , wherein the weight ratio between the taxane and the LNA oligonucleotide ranges from 50:1 to 1:25.